Noopept Nootropic

## What it is Noopept is a synthetic dipeptide developed in Russia in the 1990s by the Zakusov Research Institute of Pharmacology. It was registered in Russia in 2002 under the brand name Noopept (Lekko Pharmaceuticals) for cognitive impairment of various origins, including post-traumatic, post-stroke, and age-related cognitive decline. The compound was designed as an orally bioavailable analog of the neuropeptide cyclo-prolyl-glycine, with the practical goal of producing a piracetam-like nootropic effect at a substantially lower dose. Structurally noopept is N-phenylacetyl-L-prolylglycine ethyl ester. After oral absorption it is hydrolyzed in plasma to its active metabolite cyclo-prolyl-glycine (cycloprolylglycine), which is structurally similar to a putative endogenous neuropeptide previously isolated from rat brain. The cycloprolylglycine metabolite is the bulk of the pharmacologically active species and accounts for the prolonged effect despite the short half-life of the parent compound. The compound is marketed in Russia, Belarus, Kazakhstan, Ukraine, and several other CIS states as a prescription medication and is widely available without prescription in some neighboring jurisdictions. In the US it is unscheduled and unapproved as either drug or dietary supplement, which means it cannot be lawfully sold for human consumption but is widely available through grey-market vendors. The UK reclassified it as a prescription-only medicine in 2014. The EU regulatory status varies by member state. The per-mg potency is the most distinctive practical feature. Therapeutic doses are 10 to 30 mg/day, which is roughly 1/100th to 1/1000th of typical piracetam doses. The smaller pill burden is a meaningful adherence advantage in clinical use, and the equivalent or somewhat better cognitive endpoints in head-to-head Russian trials are the basis for the claim of greater potency. ## Mechanism of action Noopept's mechanism is multi-component and incompletely characterized by Western standards. The dominant active metabolite, cycloprolylglycine, has affinity for the AMPA glutamate receptor and modulates glutamatergic neurotransmission in hippocampus. Russian work has also reported nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) upregulation in rodent hippocampus and cortex after chronic dosing. A distinct mechanism involves protection against oxidative stress and excitotoxicity. Multiple Russian preclinical studies report reduced lipid peroxidation, reduced glutamate-induced excitotoxicity, and reduced beta-amyloid toxicity in cell culture and rodent models. The compound's neuroprotective profile is one of the strongest preclinical findings. The subjective signature in users differs from piracetam in being subtler and less stimulating. Acute effects on attention and memory are reported within 30 minutes to 2 hours of oral dosing in Russian human work, but the cognitive endpoint improvements in clinical trials accrue over 4 to 8 weeks of consistent dosing. Pharmacokinetics: oral bioavailability is around 10% for the parent compound, with rapid hydrolysis to cycloprolylglycine accounting for the majority of pharmacological activity. Peak plasma noopept is reached at 15 to 20 minutes; cycloprolylglycine peaks at 30 minutes to 2 hours. Half-life of the parent compound is 30 to 50 minutes; half-life of cycloprolylglycine is meaningfully longer (several hours), supporting twice or three-times daily dosing. Crossing the blood-brain barrier is reportedly efficient for both parent and metabolite, although precise human CNS pharmacokinetics are not well characterized. The Russian dossier reports that brain concentrations exceed plasma concentrations after oral dosing. ## Evidence base by outcome ### Cognitive impairment in stroke and TBI recovery Neznamov 2008 (n=53 post-stroke and post-TBI patients, 20 mg/day for 8 weeks) reported improvements on cognitive batteries versus placebo. Several smaller Russian trials in similar populations have produced consistent directional results. The trial sizes are modest and the follow-up windows short. ### Asthenic disorders and emotional lability Russian trials in patients with asthenic disorders, mild traumatic brain injury sequelae, and post-encephalitic cognitive impairment have reported improvements in attention, memory, and emotional regulation at 20 to 30 mg/day for 4 to 8 weeks. The trial base is the registration evidence for the Russian indication. ### Vascular cognitive impairment A 2018 Russian RCT (Amelin) compared noopept to piracetam in vascular cognitive impairment and reported equivalent or somewhat greater cognitive improvement on noopept at substantially lower doses. The head-to-head design is unusual for the Russian trial base. ### Anxiety and stress The Russian indication includes asthenic-anxiety syndrome, supported by trials reporting reductions on Hamilton Anxiety Scale at 20 to 30 mg/day. The signal is consistent but small in magnitude relative to dedicated anxiolytics. ### Healthy adult cognitive enhancement The trial base in healthy adults is essentially absent. The compound has not been tested in modern Western RCT format in non-clinical populations. The widespread off-label use in nootropic communities outside Russia rests on the clinical-population trial base plus user self-report rather than dedicated healthy-adult evidence. ### Neuroprotection (preclinical) Multiple rodent models of stroke, TBI, and neurodegeneration have shown protective effects of noopept on neuronal survival, behavioral recovery, and biomarker outcomes. The preclinical signal is one of the stronger features of the evidence base. Translation to human neuroprotection outcomes is not directly demonstrated. ### Tolerability and long-term safety Russian post-marketing surveillance covers years of clinical use. Reported adverse events are mild and similar in profile to piracetam. Long-term safety beyond 12 months has not been formally studied in modern RCT format. ## Dosage and protocols The Russian clinical dose is 20 mg/day, typically split as 10 mg twice daily with the second dose taken before mid-afternoon to avoid sleep disruption. The 30 mg/day dose appears in some protocols for more severe cognitive impairment. Doses above 30 mg/day are not characterized in modern trials and offer no documented incremental benefit. Most user protocols outside Russia follow the 20 to 30 mg/day Russian dose split into 2 to 3 doses through the day. Sublingual dosing is reported anecdotally to produce more rapid onset; the published Russian work uses oral tablets. Cycling at 4 to 8 week blocks with 2 to 4 week washouts is the conventional Russian recommendation. The mechanistic basis is partly empirical and partly speculative. Continuous use beyond 12 weeks has not been formally studied. No titration is required. Full subjective effect is reported within 1 to 2 days of starting; objective cognitive endpoint changes accrue over 4 to 8 weeks. ## Side effects and safety The side-effect profile in Russian trials is mild. Headache, irritability, sleep disturbance (especially with late-day dosing), and elevated blood pressure are reported in a small fraction of users. GI upset is uncommon. Contraindications listed in the Russian product information include pregnancy, lactation, pediatric use, severe hepatic or renal impairment, and lactose intolerance (relevant only for some formulations). The compound has not been studied in any of these populations to a Western standard. Drug interactions are not well characterized. The mild AMPA modulation and BDNF effects raise theoretical concerns with strong glutamatergic agents (memantine, ketamine) and with antidepressants, but clinical interaction data is essentially absent. The compound does not appear to interact with classical stimulants or with caffeine in any clinically significant way based on available reports. The broader safety concern for Western users is the supply chain. Noopept is not approved for human consumption outside Russia and a few neighboring jurisdictions, which means most product sold to Western users is from research-chemical vendors with no third-party identity or purity testing. Identity, purity, and dose accuracy cannot be assumed. The Russian post-marketing record over decades is reassuring on the safety axis. Reports of serious adverse events are essentially absent at therapeutic doses. The dominant unresolved questions are whether the Russian trial base would replicate in Western populations and what the long-term continuous-use safety profile looks like. ## Stack interactions and timing Noopept pairs in nootropic stack culture with choline donors (alpha-GPC, citicoline) on the same rationale as piracetam: increased cholinergic demand from the AMPA modulation may produce headache that is mitigated by added choline. The Russian clinical literature does not formally study this combination. Pairing with classical stimulants and caffeine is reported anecdotally without clear interaction concerns. Pairing with strong serotonergic or glutamatergic medications should be approached with caution given the absence of formal interaction data. The critical timing consideration is to avoid late-day dosing because of mild sleep disruption in some users. Morning and early-afternoon dosing is the standard Russian convention. ## Practical notes Noopept is one of the more interesting Russian-origin nootropics with a real clinical trial base, but the trial base is in a language and regulatory framework that Western readers cannot easily verify. The supply chain outside Russia is unregulated. Anyone using it is making an informed bet on the Russian literature plus an unregulated supply. Expect subtle subjective effects within 30 minutes to 2 hours of oral dosing, with objective cognitive endpoint improvements accruing over 4 to 8 weeks. The signature is reportedly less stimulating than piracetam and more focused on subjective clarity and mood than on raw alertness. The Russian clinical evidence base supports use in cognitive impairment of identifiable origin (post-stroke, post-TBI, vascular cognitive impairment, asthenic syndromes). Healthy-adult cognitive-enhancement use rests on inference rather than direct trial evidence.